Thermo Fisher Scientific

Drugs by trial phase (330 distinct, 352 trials)

Indications

Marketed drugs (1)

• naproxen

Subsidiaries (7 direct, 38 total across the full acquisition tree)

• Brahms AG
• Brammer Bio
• Patheon
• Phadia AB
• PPD
• Qiagen
• The Binding Site
• Acurian, Inc L2
• Banner Pharmacaps L2
• BioDuro, LLC L2
• Cellestis L2
• DSM L2
• Evidera Corporation L2
• Excel PharmaStudies, Inc. L2
• Heidelberg Clinical Research Centre L2
• Magen BioSciences L2
• Medical Research Laboratories International L2
• Research Across America L2
• Synexus L2
• Aland (Jiangsu) Nutraceutical L3
• Amyris Brasil Pesquisa e Desenvolvimento L3
• Biocare Copenhagen A/S L3
• Fortitech L3
• Kensey Nash Corporation L3
• Martek Biosciences L3
• Medimix L3
• Ocean Nutrition L3
• Osteomed Sp. z o.o L3
• Radiant Research L3
• SRF Limited L3
• Tortuga Companhia Zootécnica Agrária L3
• Twilmij L3
• Unitech Industries Ltd L3
• Valley Research Group L3
• Amerifit Brands Inc L4
• Cytori Therapeutics L4
• IntraLuminal Therapeutics L4
• Azaya Therapeutics, Inc L5

Recent trials (12)

• NCT05267613CollaboratorPhase 3Jul 1, 2022
• NCT04246762CollaboratorPhase 1Mar 1, 2020
• NCT04037176CollaboratorPhase 4Sep 1, 2019
• NCT02269566CollaboratorPhase 1Aug 1, 2014
• NCT02301884CollaboratorPhase 1Nov 1, 2013
• NCT01733134CollaboratorPhase 3Jan 1, 2013
• NCT01752569CollaboratorPhase 1/Phase 2Jun 1, 2012
• NCT02340936CollaboratorPhase 1/Phase 2Jan 1, 2011
• NCT01069965CollaboratorPhase 2Oct 1, 2010
• NCT00981058CollaboratorPhase 3Jan 1, 2010
• NCT00982111CollaboratorPhase 3Nov 1, 2009
• NCT00590915CollaboratorN/ADec 26, 2007